Exploring pharmacological interventions in benign prostate hyperplasia: the role of cost-effectiveness analysis in daily practice and future directions.

Autor:	Almusafer M; Scientific Office, U-merge Ltd, London, UK.; Department of Urology, University of Basrah, Basrah, Iraq., Narayan Y; Medical Doctor, UK., Nnorom I; Department of Urology, Homerton Healthcare NHS Foundation Trust, Homerton, UK., Karna S; Department of Urology, Milton Keynes University Hospital, Milton Keynes, UK., Katsouri A; Department of Pharmacy, Princess Alexandra Hospital, Harlow, UK., Russo GI; Urology Section, University of Catania, Catania, Italy., Morgado A; Serviço de Urologia, Centro Hospitalar Universitário São João, Porto, Portugal., Symeonidis EN; Department of Urology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece., Buchholz N; Scientific Office, U-merge Ltd, London, UK., Papatsoris A; Scientific Office, U-merge Ltd, London, UK.; 2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece., Tsampoukas G; Scientific Office, U-merge Ltd, London, UK.; Department of Urology, Homerton Healthcare NHS Foundation Trust, Homerton, UK.
Jazyk:	angličtina
Zdroj:	Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2024 May; Vol. 25 (7), pp. 907-914. Date of Electronic Publication: 2024 Jun 03.
DOI:	10.1080/14656566.2024.2362272
Abstrakt:	Introduction: Benign Prostate Hyperplasia (BPH) significantly impacts men's health and quality of life, with its prevalence rising with age. This review critically examines the cost-effectiveness of pharmacological interventions for BPH to optimize patient outcomes and healthcare resource utilization. Areas Covered: This review explores the integration of cost-effectiveness analysis (CEA) into clinical practice, balancing clinical efficacy with economic efficiency in BPH management. We performed a critical literature search, including recent studies on the economic evaluation of BPH treatments, focusing on pharmacotherapies such as alpha-blockers and 5-alpha reductase inhibitors. Additionally, we discussed the concept of CEA and evaluated the role of medicinal reconciliation and the avoidance of polypharmacy in favor of optimal BPH treatment. Expert Opinion: Cost-effectiveness analysis is crucial for evaluating BPH treatments, with evidence suggesting a shift towards surgical interventions may offer greater long-term economic benefits. However, these models must be applied cautiously, considering clinical evidence and patient preferences to ensure equitable and patient-centric healthcare.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu